News | March 17, 2008

Bristol-Myers Squibb Medical Imaging Renamed Lantheus Medical Imaging

March 18, 2008 – Today Bristol-Myers Squibb Medical Imaging introduced its new name by launching Lantheus Medical Imaging, marking the first time in the company’s 50-year history that it will operate as an independent company.

The launch builds on the momentum created by the acquisition of the business by Avista Capital Partners in January of this year. The Massachusetts-based company, acquired by Avista Capital Partners in January 2008, will continue to provide medical imaging products for nuclear and ultrasound cardiovascular diagnostic imaging procedures, including Cardiolite (Kit for the Preparation of Technetium Tc99m Sestamibi for Injection), DEFINITY Vial for (Perflutren Lipid Microsphere) Injectable Suspension and TechneLite (Technetium Tc99m Generator).

Lantheus Medical Imaging’s new President and CEO Don Kiepert said, “Lantheus Medical Imaging is well-positioned for growth with a market-leading product portfolio, promising pipeline and a world-class organization committed to the field of medical imaging. Our people are passionate about developing innovative, clinically meaningful diagnostic tools that enhance and improve patient care.”

Before joining Lantheus Medical Imaging, Kiepert was the founder and former Chairman, CEO and President of Point Therapeutics since 1996. Prior to that he was president and CEO of Chartwell Home Therapies, a home infusion services company, from 1989 to 1996. Kiepert also started and managed several health care companies and worked in various management positions at Baxter Travenol, Inc. Kiepert received his M.S. degree in clinical pharmacy from Purdue University.

For more information: www.lantheus.com

Related Content

VigiLanz and Cincinnati Children's Commercialize Real-Time Acute Kidney Injury Tracking
News | Contrast Media | November 30, 2018
VigiLanz and Cincinnati Children’s Hospital Medical Center recently announced a collaboration that leverages Cincinnati...
Gadolinium contrast agents (GBCAs) are partly retained in the brain, raising safety concerns, as seen in this MRI.

Gadolinium contrast agents (GBCAs) are partly retained in the brain, raising safety concerns, as seen in this MRI.

News | Contrast Media | September 12, 2018
In February 2018, a workshop was held at the National Institutes of Health (NIH) in Bethesda, Maryland, to explore co
Ligand Establishes Program to Develop Captisol-Enabled, Next-Generation Diagnostic Imaging Contrast Agents
News | Contrast Media | January 19, 2018
Ligand Pharmaceuticals Inc. announced initiation of a program to develop contrast agents with reduced renal toxicity....
FDA Holds MIDAC Meeting on Gadolinium-Based Contrast Agents. Image by Marilyn Fornell
News | Contrast Media | September 07, 2017
The U.S. Food and Drug Administration (FDA) announced it would hold a meeting of the Medical Imaging Drugs Advisory...
European Medicines Agency Issues Update on Gadolinium Contrast Agents
News | Contrast Media | August 29, 2017
August 29, 2017 — The European Medicines Agency (EMA) issued a final opinion that recommended restricting the use of
Guerbet Announces Plans to Streamline Contrast Media Portfolio, gadolinium MRI contrast
News | Contrast Media | July 18, 2017
Guerbet recently announced that it will phase out sales throughout the world of two products: Hexabrix (meglumine and...
ACR Offers Revised Contrast Media in Imaging Manual
News | Contrast Media | July 17, 2017
The American College of Radiology (ACR) recently revised its authoritative guide for the safe and effective use of...
Bayer Arterion contrast Injector used to administer medical imaging contrast for CT scans.

Bayer Healthcare's Arterion contrast injector system.

Feature | Contrast Media | June 19, 2017 | Dave Fornell
Here are several updates in medical imaging...
PRAC, European Medicines Agency, gadolinium-based contrast agents, safety recommendations, brain MRI
News | Contrast Media | March 13, 2017
The Pharmacovigilance Risk Assessment Committee (PRAC) of the European Medicines Agency recently released new...
Lantheus Medical Imaging, Definity, FDA approval, label update, echocardiography, cardiac shunt contraindication
Technology | Contrast Media | February 02, 2017
Lantheus Medical Imaging Inc. announced U.S. Food and Drug Administration (FDA) approval of a label update for Definity...
Overlay Init